Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448655 | 1.00 | SPHK1 (0.48) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL19481651 | 1.00 | SPHK1 (0.48) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL27303527 | 0.89 | SPHK1 (0.49) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL1776217 | 0.86 | SPHK1 (0.47) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL15319039 | 0.85 | SPHK1 (0.50) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL15319038 | 0.85 | SPHK1 (0.50) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL24554698 | 0.85 | SPHK1 (0.46) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL3450154 | 0.85 | SPHK1 (0.46) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL5892729 | 0.84 | SPHK1 (0.44) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL23341555 | 0.84 | SPHK1 (0.46) | SPHK1BRD4CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109970764-B | Synthesis method of (S) -1,1,5, 5-tetramethyl dihydro oxazolo [3,4-c ] oxazol-3-one | 上海吉奉生物科技有限公司 | 2021-11-09 | — | — | CN | claimed |
| US-20240317775-A1 | H4 Antagonist Compounds | NXERA PHARMA UK LIMITED (GB) | 2024-09-26 | — | — | US | disclosed |
| EP-4259637-A1 | H4 ANTAGONIST COMPOUNDS | Heptares Therapeutics Limited (GB) | 2023-10-18 | — | — | EP | disclosed |
| CN-116848125-A | H4 antagonist compounds | 赫帕雷斯治疗有限公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2022129890-A1 | H4 ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022129890-A1 | H4 ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| CN-109970764-B | Synthesis method of (S) -1,1,5, 5-tetramethyl dihydro oxazolo [3,4-c ] oxazol-3-one | 上海吉奉生物科技有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-109970764-B | Synthesis method of (S) -1,1,5, 5-tetramethyl dihydro oxazolo [3,4-c ] oxazol-3-one | 上海吉奉生物科技有限公司 | 2021-11-09 | — | — | CN | disclosed |
| US-9458177-B2 | Oxazolidin-2-one compounds and uses thereof | NOVARTIS AG (CH) | 2016-10-04 | — | — | US | disclosed |
| US-9458177-B2 | Oxazolidin-2-one compounds and uses thereof | NOVARTIS AG (CH) | 2016-10-04 | — | — | US | disclosed |
| US-20140378450-A1 | OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2014-12-25 | — | — | US | disclosed |
| US-20140378450-A1 | OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2014-12-25 | — | — | US | disclosed |
| US-8865894-B2 | Oxazolidin-2-one compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-8865894-B2 | Oxazolidin-2-one compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-8865894-B2 | Oxazolidin-2-one compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130225574-A1 | OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2013-08-29 | — | — | US | disclosed |
| US-20130225574-A1 | OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2013-08-29 | — | — | US | disclosed |
| US-20130225574-A1 | OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2013-08-29 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | SPHK1 3746/4885BRD4 346/4885CHRM2 35/4885 |
| US-20240317775-A1 | H4 Antagonist Compounds | HRH4, HRH3, H1-4 | SPHK1 1508/4885BRD4 145/4885CHRM2 4/4885 |
| US-20140378450-A1 | OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | SPHK1 825/4885BRD4 1459/4885CHRM2 4881/4885 |
| US-20130225574-A1 | OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | SPHK1 825/4885BRD4 1459/4885CHRM2 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.